Adding the new shares to the mix at Lucent would reduce its estimated 2004 earnings by 4 percent, Haushalter said. At Interpublic, the additional shares would cut earnings by 6.7 percent, and at Watson Pharmaceuticals, the figure would drop by 5.4 percent.
"As market conditions continue to improve, more and more of these situations arise where companies get closer to contingency prices," Haushalter said. "But it is not clear to me that investors are aware of this."
Just two more reasons to keep your pencils sharp.
RSS